Have any thoughts about
Medibio Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-68.1
Current
-68.1
Median
12.7
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-68.1
=
Enterprise Value
121.8m AUD
/
EBITDA
-1.8m AUD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
AU
Medibio Ltd
ASX:MEB
Average EV/EBITDA: 102.7
Negative Multiple: -68.1
N/A N/A
US
Veeva Systems Inc
NYSE:VEEV
44.6
221%
0.2
US
C
Cerner Corp
LSE:0R00
21.9
N/A N/A
AU
Pro Medicus Ltd
ASX:PME
220.8
130%
1.7
US
Doximity Inc
NYSE:DOCS
47.5
92%
0.5
US
W
Waystar Holding Corp
NASDAQ:WAY
25.2
N/A N/A
JP
M3 Inc
TSE:2413
11.8
24%
0.5
US
Inspire Medical Systems Inc
NYSE:INSP
281.3
N/A N/A
SE
Sectra AB
STO:SECT B
Negative Multiple: -71.1 N/A N/A
US
V
Vocera Communications Inc
F:V00
238.8
N/A N/A
CN
Winning Health Technology Group Co Ltd
SZSE:300253
32
143%
0.2

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More